Bioorganic & Medicinal Chemistry Letters 2012-08-01

Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.

Tim H M Jonckers, Marie-Claude Rouan, Geerwin Haché, Wim Schepens, Sabine Hallenberger, Judith Baumeister, Jennifer C Sasaki

Index: Bioorg. Med. Chem. Lett. 22(15) , 4998-5002, (2012)

Full Text: HTML

Abstract

A new class of benzoxazole and benzothiazole amide derivatives exhibiting potent CYP3A4 inhibiting properties was identified. Extensive lead optimization was aimed at improving the CYP3A4 inhibitory properties as well as overall ADME profile of these amide derivatives. This led to the identification of thiazol-5-ylmethyl (2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate (C1) as a lead candidate for this class. This compound together with structurally similar analogues demonstrated excellent 'boosting' properties when tested in dogs. These findings warrant further evaluation of their properties in an effort to identify valuable alternatives to Ritonavir as pharmacokinetic enhancers.Copyright © 2012 Elsevier Ltd. All rights reserved.